mepolizumab

Details

Generic Name:

mepolizumab

Project Status:

Not filed

Therapeutic Area:

Asthma, severe eosinophilic (pediatric)

Manufacturer:

GlaxoSmithKline Inc.

Brand Name:

Nucala

Project Line:

Reimbursement Review

Project Number:

N/A

Manufacturer Requested Reimbursement Criteria¹:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Submission Type:

Non Submission

Indications:

Adolescents and children (aged 6 years and older) who are inadequately controlled with medium-to-high-dose inhaled corticosteroids and an additional asthma controller (e.g., LABA); and who have a blood eosinophil count of ≥ 150 cells/mcL (0.15 GI/L) at initiation of treatment with Nucala OR ≥ 300 cells/mcL (0.3 GI/L) in the past 12 months.

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : October 16, 2023